BRCA1 and posterior cortical atrophy: The importance of the BRCA1/2 test in patients with PCa is justified by several reasons: it has been shown that the PVs of the BRCA genes, whether of a germinal or somatic nature, represent a predictive biomarker of greater sensitivity to treatment with inhibitors of the enzyme PARP in patients with hormone-resistant metastatic prostate cancer [1,6,7].